A new study published in Cancers last week has shown a dramatically high rate of cancers for Zantac users. The cancers linked to Zantac use include gastro and colorectal cancer.
The study notes, "The majority of these studies have focused on cancers of the gastrointestinal system; of those studies, gastric cancer has received the most attention. In a meta-analysis, Song et al. reported." This indicates users of the recalled heartburn drug may face a three-fold increased risk of developing gastrointestinal cancer due to the chemical byproduct N-nitrosodimethylamine (NDMA), which is produced by the active ingredient ranitidine. at high levels of dietary NDMA exposure were associated with a statistically significant 34% increase in the risk of gastric cancer.
Zantac and other generic ranitidine drugs have been used by millions of Americans for years to prevent and relieve heartburn and they were marketed as safe and effective even for long-term use. However, all versions of the medication were pulled from the market earlier this year, after it was discovered the pills commonly contained extremely high and dangerous levels of NDMA, which is a potent human carcinogen.
The problems were first identified by researchers at the independent pharmacy Valisure, which began testing all medications for NDMA after the chemical resulted in widespread recalls for valsartan, irbesartan, losartan and other widely used generic blood pressure drugs. However, unlike those recalls, where NDMA was created as a byproduct of changes in the generic drug making process, Valisure determined that Zantac problems involved the active ingredient ranitidine converting to NDMA over time when introduced to high heat during storage, or even as it is digested inside the human body.
In this latest study, researchers looked at adverse events reported to the FDA linked to the use of different types of medications used to prevent or treat heartburn, including proton pump inhibitors (PPIs), and H2 antagonists. Zantac is a member of the latter class. The researchers then compared the proportionate reporting rations (PPR) between the different medications.
However, the news about Zantac's association with gastrointestinal cancer isn't the only shocking news to come from this report. The rates of colorectal cancer for users of Zantac is 16 times higher for Zantac users than for those who used other heartburn medications.
The study confirms what we've been experiencing with those Zantac users who have contacted us. This is a dangerous drug and its association with cancer is becoming clearer as new studies are published.
You may be able to file a Zantac cancer lawsuit if you developed cancer while consuming Zantac for a prolonged period of time. Use the contact form on this page for a free case evaluation by one of our experienced dangerous drug attorneys. You may also call our office directly at (888) 260-0473 to discuss your Zantac cancer lawsuit and possible settlement. At Rheingold Giuffra Ruffo & Plotkin LLP, our New York defective drug lawyers handle cases directly and do not refer them to other firms.